A randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo.
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Phase 2 window study of two dose levels of SAR439859 (SERD) versus letrozole in newly diagnosed preoperative post-menopausal patients with ER positive, HER2 negative primary breast cancer
Seattle Genetcs SGNTUC-016 HER2CLIMB-02
Randomized, Double Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Patients with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma
A Randomized, Multicenter, Open-Label, Two-Arm, Phase Ii, Neoadjuvant Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Gdc-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib For Postmenopausal Women With Estrogen Receptor-Positive And Her2-Negative Untreated Early Breast Cancer
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
A Randomized, Multi Center, Double-blind, Placebo Controlled Phase 3 Study of Nivolumab Versus Placebo in Com ibnation with Neoadjuvant Endocrine Therapy in the Treatment of High-Risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Breast Cancer
A phase III, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.